New Analytical Approach for the Determination of Calcium
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Role and Fate of Added Phosphates in Salted Cod Products
The role and fate of added phosphates in salted cod products Kristín Anna Þórarinsdóttir Sigurjón Arason Guðjón Þorkelsson Nýsköpun og neytendur Skýrsla Matís 27-10 Júlí 2010 ISSN 1670-7192 Titill / Title The role and fate of added phosphates in salted cod products / Hlutverk og afdrif viðbætts fosfats í saltfiski Höfundar / Authors Kristín Anna Þórarinsdóttir, Sigurjón Arason, Guðjón Þorkelsson Skýrsla / Report no. 27‐10 Útgáfudagur / Date: Júlí 2010 Verknr. / project no. 1008‐1934, 1008‐1935 Styrktaraðilar / funding: AGS, AVS Ágrip á íslensku: Markmið verkefnisins var að meta afdrif viðbætts fosfats í saltfiski. Ljóst er að magn þess lækkar við verkun og útvötnun. Sama gildir um fosföt sem eru náttúrulega til staðar í fiskvöðva. Þess vegna er heildarmagn fosfats í útvötnuðum afurðum yfirleitt lægra en í ferskum fiski. Hins vegar hefur verið sýnt fram á að viðbætt fosföt (dí‐ og trífosföt) finnast bæði í verkuðum og útvötnum fiski. Það er þó háð magni viðbætts fosfats í afurðinni og hvaða söltunarferlum er beitt, þ.e. hvort fosfati var bætt í fiskinn með sprautun eða pæklun. Lítið eða ekkert greinist í útvötnuðum afurðum ef pæklun er beitt. Munur á milli ferla getur stafað af söltunaraðferð (sprautun/pæklun), gerð og upphaflegu magni viðbætts fosfats og verkunartíma. Frekari rannsókna er þörf til að meta áhrif af mismunandi söltunarferlum á afdrif fosfats í söltuðum þorskvöðva. Lykilorð á íslensku: Saltfiskur, viðbætt fosfat, niðurbrot, verkunarferlar, sprautun, pæklun Summary in English: The aim of this study was to investigate the fate of added phosphates in salted cod products. The content of both added phosphates and naturally occurring phosphates, decreases during salting and rehydration. -
Effect of the Addition of Alginate And/Or Tetracycline on Brushite Cement Properties
molecules Article Effect of the Addition of Alginate and/or Tetracycline on Brushite Cement Properties Claudia Morilla 1,2,3, Elianis Perdomo 4, Ana Karla Hernández 1, Ramcy Regalado 1, Amisel Almirall 1, Gastón Fuentes 1,2,* , Yaima Campos Mora 1,2, Timo Schomann 2,3 , Alan Chan 3 and Luis J. Cruz 2 1 Biomaterials Center, University of Havana, La Habana 10400, Cuba; [email protected] (C.M.); [email protected] (A.K.H.); [email protected] (R.R.); [email protected] (A.A.); [email protected] (Y.C.M.) 2 Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; [email protected] (T.S.); [email protected] (L.J.C.) 3 Percuros B.V., 2333 CL Leiden, The Netherlands; [email protected] 4 Faculty of Automatic and Biomedical Engineering, Technological University of Havana, La Habana 11300, Cuba; [email protected] * Correspondence: [email protected] or [email protected] Abstract: Calcium phosphate cements have the advantage that they can be prepared as a paste that sets in a few minutes and can be easily adapted to the shape of the bone defect, which facilitates its clinical application. In this research, six formulations of brushite (dicalcium phosphate dihydrated) cement were obtained and the effect of the addition of sodium alginate was analyzed, such as its capacity as a tetracycline release system. The samples that contain sodium alginate set in 4 or 5 min Citation: Morilla, C.; Perdomo, E.; and showed a high percentage of injectability (93%). -
Calcium Phosphate Bioceramics: a Review of Their History, Structure, Properties, Coating Technologies and Biomedical Applications
Review Calcium Phosphate Bioceramics: A Review of Their History, Structure, Properties, Coating Technologies and Biomedical Applications Noam Eliaz * and Noah Metoki Biomaterials and Corrosion Lab, Department of Materials Science and Engineering, Tel-Aviv University, Ramat Aviv 6997801, Israel; [email protected] * Correspondence: [email protected]; Tel.: +972-3-640-7384 Academic Editor: Patrice Laquerriere Received: 11 February 2017; Accepted: 22 March 2017; Published: 24 March 2017 Abstract: Calcium phosphate (CaP) bioceramics are widely used in the field of bone regeneration, both in orthopedics and in dentistry, due to their good biocompatibility, osseointegration and osteoconduction. The aim of this article is to review the history, structure, properties and clinical applications of these materials, whether they are in the form of bone cements, paste, scaffolds, or coatings. Major analytical techniques for characterization of CaPs, in vitro and in vivo tests, and the requirements of the US Food and Drug Administration (FDA) and international standards from CaP coatings on orthopedic and dental endosseous implants, are also summarized, along with the possible effect of sterilization on these materials. CaP coating technologies are summarized, with a focus on electrochemical processes. Theories on the formation of transient precursor phases in biomineralization, the dissolution and reprecipitation as bone of CaPs are discussed. A wide variety of CaPs are presented, from the individual phases to nano-CaP, biphasic and triphasic CaP formulations, composite CaP coatings and cements, functionally graded materials (FGMs), and antibacterial CaPs. We conclude by foreseeing the future of CaPs. Keywords: bioceramics; biomineralization; bone cement; calcium phosphate; coating; composites; drug delivery; electrochemical deposition; functionally graded materials; nano-hydroxyapatite 1. -
Studies on Metal Complex Formation of Environmentally Friendly Aminopolycarboxylate Chelating Agents
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Helsingin yliopiston digitaalinen arkisto Studies on metal complex formation of environmentally friendly aminopolycarboxylate chelating agents Helena Hyvönen Laboratory of Inorganic Chemistry Department of Chemistry Faculty of Science University of Helsinki Finland Academic dissertation To be presented with the permission of the Faculty of Science of the University of Helsinki for public criticism in Auditorium A110 of the Department of Chemistry, A.I. Virtasen aukio 1, on June 25th 2008 at 12 o’clock noon Helsinki 2008 Supervisor Professor Heikki Saarinen Department of Chemistry University of Helsinki Finland Reviewers Professor Konstantin Popov Physical and Colloid Chemistry Department Moscow State University of Food Production Russia Professor Mika Sillanpää Department of Environmental Sciences University of Kuopio Finland Opponent Professor Lauri Lajunen Department of Chemistry University of Oulu Finland © Helena Hyvönen ISBN 978-952-92-4005-0 (paperback) ISBN 978-952-10-4741-1 (PDF) http://ethesis.helsinki.fi Yliopistopaino Helsinki 2008 2 Abstract For decades, ethylenediaminetetraacetic acid (EDTA) and other aminopolycarboxylates with similar complexation properties and applicability have been widely used as chelating agents in various branches of industry. Recently, the low biodegradability of these ligands and their accumulation in the environment has become cause for concern, because of the persistence of these ligands and their metal complexes in nature. Ethylenediaminedisuccinic acid (EDDS), iminodisuccinic acid (ISA), N-bis[2-(1,2- dicarboxyethoxy)ethyl]aspartic acid (BCA6), N-bis[2-(1,2-dicarboxyethoxy)ethyl]- glycine (BCA5), N-bis[2-(1,2-dicarboxyethoxy)ethyl]methylglycine (MBCA5) and N- tris[(1,2-dicarboxy-ethoxy)ethyl]amine (TCA6) are more environmentally benign and potential candidates to replace EDTA, and also diethylenetriaminepentaacetic acid (DTPA), in several applications. -
S1508 2.5 KG Sodium Tripolyphosphate
Scientific Documentation S1508, Sodium Tripolyphosphate, FCC Not appropriate for regulatory submission. Please visit www.spectrumchemical.com or contact Tech Services for the most up‐to‐date information contained in this information package. Spectrum Chemical Mfg Corp 769 Jersey Avenue New Brunswick, NJ 08901 Phone 732.214.1300 Ver4.01 27.April.2016 Dear Customer, Thank you for your interest in Spectrum’s quality products and services. Spectrum has been proudly serving our scientific community for over 45 years. It is our mission to manufacture and distribute fine chemicals and laboratory products with Quality and delivery you can count on every time. To accomplish our mission, Spectrum utilizes our sourcing leverage and supplier qualification expertise in offering one of the industry’s most comprehensive line of fine chemical products under one brand, in packaging configurations designed to meet your research and production requirements. Our product grades include: USP, NF, BP, EP, JP, FCC, ACS, KSA, Reagent grade, as well as DEA controlled substances. We operate facilities in the United States on the East Coast, West Coast, as well as in Shanghai, China in order to provide the best logistical support for our customers. At Spectrum, Quality is priority number one. Suppliers with the best qualifications are preferred and we employ full-functioning in-house analytical laboratories at each of our facilities. Our facilities and systems are USFDA registered and ISO certified. We frequently host customer audits and cherish opportunities for improvements. Quality is engrained into our culture. Quality is priority number one. In the following pages, we have designed and prepared documented scientific information to aid you in your initial qualification or your continual use of our products. -
Role of Strontium on the Crystallization of Calcium Hydrogen Phosphate Dihydrate (CHPD)
Journal of Minerals & Materials Characterization & Engineering , Vol. 10, No.7, pp.625-636, 2011 jmmce.org Printed in the USA. All rights reserved Role of Strontium on the Crystallization of Calcium Hydrogen Phosphate Dihydrate (CHPD) K. Suguna 1, 2 , C. Sekar 3* 1 Department of Physics, Sri Sarada College for Women, Salem -636 016, TN, India. 2 Department of Physics, Periyar University, Salem- 636 011, TN, India. 3 Department of Bioelectronics and Biosensors, Alagappa University, Karaikudi-630003, TN, India. *Corresponding Author: [email protected] ABSTRACT Calcium hydrogen phosphate dihydrate (CHPD, CaHPO 4· 2H2O) or brushite is found quite frequently in urinary calculi (stones) . Crystallization of brushite has been carried out in sodium metasilicate (SMS) gel with and without adding ‘Sr’ as additive. In pure system, dicalcium phosphate anhydrous (DCPA, CaHPO 4) or monetite and hydroxyapatite (HA, Ca 5(PO 4)3(OH)) grew along with brushite. The presence of Sr suppressed the formation of HA and enhanced the number and size of monetite crystals and changed the morphology of brushite crystals from needle shape to octopus-like shape. The samples were characterized by powder & single crystal X-ray diffraction (XRD), scanning electron microscopy (SEM), X- ray fluorescence spectroscopy (XRF), Fourier transform infrared spectroscopy (FTIR) and thermal analyses (TG-DTA) . Keywords: Brushite , Crystal growth, Sr additive, SEM. 1. INTRODUCTION Calcium phosphates have been studied extensively because of their occurrence in normal and pathological calcifications. Due to their excellent biocompatibility, it is a well-known bioactive material suitable for bone and hard tissue replacement [1] . Hydroxyapatite (HA, Ca 5(PO 4)3(OH), octacalcium phosphate (OCP,Ca 8H2(PO 4)6·5(H 2O)), tricalcium phosphate ( β- TCP, Ca 3(PO 4)2), dicalcium phosphate dihydrate or calcium hydrogen phosphate dihydrate (CHPD, CaHPO 4·2H 2O), dicalcium phosphate anhydrous (DCPA, CaHPO4), tetracalcium [2] phosphate (TTCP, Ca 4(PO 4)2O) and amorphous calcium phosphate (ACP) are different 625 626 K. -
(12) United States Patent (10) Patent No.: US 9,023,145 B2 Galembeck Et Al
USOO90231.45B2 (12) United States Patent (10) Patent No.: US 9,023,145 B2 Galembeck et al. (45) Date of Patent: May 5, 2015 (54) ALUMINUM PHOSPHATEOR (58) Field of Classification Search POLYPHOSPHATE COMPOSITIONS USPC .................................. 106/31.13, 287.17, 401 See application file for complete search history. (75) Inventors: Fernando Galembeck, Campinas (BR): Cesar Augusto Sales Barbosa, (56) References Cited Campinas (BR); Melissa Braga, Campinas (BR) U.S. PATENT DOCUMENTS (73) Assignee: Bunge Amorphic Solutions LLC, White 1,654.404 A 12/1927 Blumenberg, Jr. Plains, NY (US) 2,222, 198 A * 1 1/1940 Fleck ......................... 162,1812 (Continued) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 730 days. BR IP 9500.522-6 6, 2002 (21) Appl. No.: 12/368,867 BR IP 94.00746-2 T 2003 (Continued) (22) Filed: Feb. 10, 2009 OTHER PUBLICATIONS (65) Prior Publication Data Chemical Book. CAS DataBase List. "Sodium Polyphosphate” US 2009/0217841 A1 Sep. 3, 2009 (2010). http://www.chemicalbook.com/ChemicalProductProperty EN CB0278207.htm.* Related U.S. Application Data (Continued) (60) Provisional application No. 61/065,493, filed on Feb. 12, 2008. Primary Examiner — Kaj K Olsen (51) Int. Cl. Assistant Examiner — Ross J Christie C4B I4/0 (2006.01) (74) Attorney, Agent, or Firm — Snell & Wilmer L.L.P. C09C I/40 (2006.01) B82/30/00 (2011.01) (57) ABSTRACT COIB 25/24025/36 (2006.01)2006.O1 Slurry composition comprising amorphous aluminum phos CSK 3/32 (2OO 6. O R phate, polyphosphate orthophosphate, metaphosphate and/or C09D 5/02 (2OO 6. -
Inhibitors and Promoters of Stone Formation
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 13 (1978), pp. 361—3 71 Inhibitors and promoters of stone formation HERBERT FLEISCH Department of Pathophysiology, University of Berne, Berne, Switzerland Currently, three main mechanisms are thought to Crystal growth and crystal aggregation be important in the formation of urinary stones: 1) In the past, attention was devoted mostly to the the relationship between the concentration of the formation and growth of crystals. Recently, interest precipitating substances in urine and the solubility of has been directed to an area which, until now, had the mineral phase formed, 2) the role of promoters of been neglected: the crystal aggregation. This term crystallization and aggregation, and 3) the part describes the process of crystals binding one to an- played by inhibitors of crystal formation and aggre- other, resulting in the formation of larger clusters. In gation (Fig. 1). vitro, aggregation of both calcium oxalate [16, 17] Saturation of urine and calcium phosphate crystals [18] occurs readily when the solution is supersaturated. Aggregation It is now widely accepted that even in normal could be the mechanism which distinguishes simple people, urine is ordinarily supersaturated with re- crystalluria, which occurs in most normal people, spect to calcium oxalate [1—6], octocalcium phos- from stone formation. This line of thought is phate [2, 3], hydroxyapatite [1, 2], and sometimes strengthened by the finding that while usually only with respect to brushite [1, 7, 8]. The degree of individual calcium oxalate crystals are found in nor- supersaturation is usually higher in patients with mal people, stone-formers often excrete large aggre- urinary stones [2—4, 7—10]. -
Dicalcium Phosphate As a Mineral Supplement for Dairy Cows
BULLETIN 455 AUGUST, 1930 Dicalcium Phosphate as a Mineral Supplement for Dairy Cows C. C. Hayden, C. F. Monroe, and C. H. Crawford OHIO AGRICULTURAL EXPERIMENT STATION Wooster, Ohio CONTENTS Introduction . • . • . • • . • • . • • • • • • . •.......•••.•.•••••••••••••• , • • . • • . • .. 3 Review of Other Work . .. .. .. 3 Metabolism Experiments . • . 3 Feeding Trials . 5 Experiment . 7 Plan ........................................................... 7 Cows Used ....................................................... 7 Care and Feeding . 7 Mineral Used . 8 Results ............................................................ 8 Milk Production ................................................. 8 Total Production ............................................ 9 Total Production Corrected to 4 Per Cent Fat Basis . 10 Corrected for Length of Lactation . • . 10 Corrected for Age . 11 Other Comparisons . 12 Periods Before and After Feeding Minerals Compared . 12 First and Second Lactations of Heifers Compared . 13 Summary of Milk Production . 13 Health of the Herd . 15 Condition of the Cows . 15 Breeding . • . 15 Diseases . ....................................... 16 General Discussion .................................................. 16 Summary and Conclusions ........................................... 18 References Cited .................................................... 19 Appendix • • . • • . • • • • . • . • . • • • . .•.•...••••••••••• , , • , , • , ....... 21 (1) Trumbull County Experiment Farm barn where the experiment was conducted DICALCIUM -
Kidney Disease and Your Diet
Kidney Disease and Your Diet Kidney Disease and Your Diet Department of Nutrition Services Kidney and Urinary Program 1 Kidney Disease and Your Diet PD 3085 (Rev 2015-10) File: peyles 2 Kidney Disease and Your Diet Inside this book Page About your kidneys 1 Protein 3 Potassium 6 Phosphorus 11 Sodium (Salt) 17 Herb and Spice Guide 21 Fluids 22 Staying a Healthy Weight 24 Bread, Grains and Other Starches 26 Fats 27 Sugar and Sugar Containing Food 28 Your Daily Choices 29 Sample Menu Plan 30 Tips on Eating Out 32 Reading Labels 39 3 Kidney Disease and Your Diet About your kidneys Your kidneys are shaped like kidney beans. Each one is the size of your fist. A kidney has about 1 million tiny filters inside. What do kidneys do? Kidneys have 3 main jobs . They filter and remove waste from blood and make urine. kidney = = filter out wastes in urine They control the salt and water balance in your body. They produce hormones that help make red blood cells and keep your bones healthy. What happens when kidneys have a disease? Kidney disease affects all the jobs that healthy kidneys do. Kidneys with a disease do not remove waste out of your body very well. Wastes start to build up in your body. Where does the waste come from? Waste comes from the food we eat. Our food is made up of proteins, fat and starches. When we eat food, the body digests it. The blood absorbs the digested food and takes it to all the cells to be used. -
Chemical Specific Parameters May 2019
Regional Screening Level (RSL) Chemical-specific Parameters Supporting Table April 2019 Contaminant Molecular Weight Volatility Parameters Melting Point Density Diffusivity in Air and Water Partition Coefficients Water Solubility Tapwater Dermal Parameters H` HLC H` and HLC VP VP MP MP Density Density Dia Diw Dia and Diw Kd Kd Koc Koc log Kow log Kow S S B τevent t* Kp Kp Analyte CAS No. MW MW Ref (unitless) (atm-m3/mole) Ref mmHg Ref C Ref (g/cm3) Ref (cm2/s) (cm2/s) Ref (L/kg) Ref (L/kg) Ref (unitless) Ref (mg/L) Ref (unitless) (hr/event) (hr) (cm/hr) Ref Acephate 30560-19-1 1.8E+02 PHYSPROP 2.0E-11 5.0E-13 EPI 1.7E-06 PHYSPROP 8.8E+01 PHYSPROP 1.4E+00 CRC89 3.7E-02 8.0E-06 WATER9 (U.S. EPA, 2001) 1.0E+01 EPI -8.5E-01 PHYSPROP 8.2E+05 PHYSPROP 2.1E-04 1.1E+00 2.7E+00 4.0E-05 EPI Acetaldehyde 75-07-0 4.4E+01 PHYSPROP 2.7E-03 6.7E-05 PHYSPROP 9.0E+02 PHYSPROP -1.2E+02 PHYSPROP 7.8E-01 CRC89 1.3E-01 1.4E-05 WATER9 (U.S. EPA, 2001) 1.0E+00 EPI -3.4E-01 PHYSPROP 1.0E+06 PHYSPROP 1.3E-03 1.9E-01 4.5E-01 5.3E-04 EPI Acetochlor 34256-82-1 2.7E+02 PHYSPROP 9.1E-07 2.2E-08 PHYSPROP 2.8E-05 PHYSPROP 1.1E+01 PubChem 1.1E+00 PubChem 2.2E-02 5.6E-06 WATER9 (U.S. -
Roclean P112 SAFETY DATA SHEET
RoClean P112 SAFETY DATA SHEET 1. Company and Product Identification 1.1 Identification – Product Name : RoClean P112 Other means of identification Organic and Inorganic Salts 1.2 Synonym: Mixture, none Recommended Use Of The Chemical Membrane filtration or ultrafiltration process cleaner 1.3 and Restrictions On Use: Use only as directed on the label. Name , Address, And Telephone Number Of AVISTA TECHNOLOGIES The Manufacturer, Or Other Responsible Party: 140 Bosstick Street 1.4 San Marcos, CA 92069 (760) 744-0536 Competent Person email address [email protected] 24 Hour Emergency No.: 1-800-424-9300 (United States) 1.5 1-703 527-3887 (International Collect) DRINKING WATER TREATMENT ADDITIVES CLASSIFIED BY NSF INTERNATIONAL TO ANSI/NSF 60 AS STANDARD DRINKING WATER TREATMENT CHEMICAL FOR USE OFF - LINE IN REVERSE OSMOSIS SYSTEMS 2. HAZARD S IDENTIFICATION EMERGENCY OVERVIEW: This product is an odorless, white to cream colored solid. This product can irritate contaminated skin, eyes, mucous membranes, and any other exposed tissues. This product is neither reactive nor flammable. Thermal decomposition of this product produces irritating vapors and toxic gases (e.g., carbon oxides, phosphorus oxides, and sodium oxides). Emergency responders must wear personal protective equipment (and have appropriate fire -extinguishing protection) suitable for the situation to which they are responding. Physical Hazards Summary This product is a moderate skin or eye irritant Potential Health Hazards Summary Skin Corrosion/Irritation - Category 2 Serious Eye Damage Eye Irritation - Category 2A Acute toxicity oral, Category 3 Potential Ecological Effects Summary Acute Hazards to the aquatic environment – Category 3 2.1 Classification Of Product U.S.